Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Johnson_&_Johnson
|
| gptkbp:acquisitionYear |
2011
|
| gptkbp:country |
gptkb:Netherlands
|
| gptkbp:delistedDate |
gptkb:Euronext_Amsterdam
2011 |
| gptkbp:focusesOn |
vaccines
antibodies |
| gptkbp:foundedIn |
1993
|
| gptkbp:headquartersLocation |
gptkb:Leiden
|
| https://www.w3.org/2000/01/rdf-schema#label |
Crucell
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Euronext_Amsterdam
|
| gptkbp:notableProduct |
gptkb:Epaxal
Inflexal V Quinvaxem |
| gptkbp:parentCompany |
gptkb:Johnson_&_Johnson
|
| gptkbp:researchArea |
immunology
infectious diseases |
| gptkbp:website |
https://www.crucell.com
|
| gptkbp:bfsParent |
gptkb:强生
|
| gptkbp:bfsLayer |
5
|